Paper Details

  1. Home
  2. Paper Details

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis.

Author: EngertAndreas, MonsefIna, RanceaMichaela, SkoetzNicole, von TresckowBastian

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

While most people with Hodgkin lymphoma are successfully treated, about 15% experience a relapse. This study reviewed research on using high-dose chemotherapy (HDCT) followed by a stem cell transplant (ASCT) for patients with relapsing Hodgkin lymphoma. The review found that this approach may delay the return of cancer, but it did not show a clear improvement in overall survival compared to standard chemotherapy. The study also found a slight increase in infections and deaths related to treatment when HDCT was given before HDCT and ASCT.
Paper Details　
Original Abstract of the Article :
Treatment for Hodgkin lymphoma is effective for about 85% of the patients. A gold-standard for the 15% of relapsing patients is still missing. High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) has shown efficacy and safety for patients, but up to date no survival ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.critrevonc.2014.04.003

データ提供：米国国立医学図書館（NLM）

A Systematic Review of High-Dose Chemotherapy for Relapsed Hodgkin Lymphoma

This systematic review and meta-analysis examines the efficacy and safety of high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) for patients with relapsed or refractory Hodgkin lymphoma. It's like meticulously mapping a vast desert landscape, seeking the most effective path for patients facing this challenging disease. The review reveals that while HDCT followed by ASCT shows promising results in terms of progression-free survival, there is no clear evidence of a survival benefit compared to conventional chemotherapy. However, the review highlights the potential for increased infections and treatment-related mortalities in patients receiving sequential HDCT plus ASCT compared to HDCT plus ASCT. This study provides valuable insights into the complex landscape of Hodgkin lymphoma treatment, emphasizing the need for careful consideration of treatment options and potential risks.

High-Dose Chemotherapy: A Potential but Complex Treatment

This systematic review highlights the complex landscape of Hodgkin lymphoma treatment. While HDCT followed by ASCT offers potential benefits, it also presents significant challenges and risks. It's a reminder that even in the vast desert of cancer treatment, there are no simple solutions, and careful consideration is crucial in selecting the most appropriate approach for individual patients.

Navigating Hodgkin Lymphoma Treatment: A Balancing Act

This research underscores the importance of carefully weighing the potential benefits and risks associated with high-dose chemotherapy followed by autologous stem cell transplantation in the treatment of relapsed Hodgkin lymphoma. It's a reminder that the desert of cancer treatment is filled with both challenges and opportunities, and finding the right path requires careful navigation and collaboration between patients and their healthcare providers.

Dr. Camel's Conclusion

This systematic review provides valuable insights into the complexities of Hodgkin lymphoma treatment. While HDCT followed by ASCT shows promising results, it's important to carefully consider the potential risks and benefits for each patient. The search for more effective and safer treatments continues, and this study underscores the need for ongoing research in this field.
Date :
  1. Date Completed 2015-05-27
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24855908

DOI: Digital Object Identifier

10.1016/j.critrevonc.2014.04.003

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.